A recent guideline update (ZM Younossi. Liver Transplantation 2018; 24: 166-70) provides some useful information about nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and liver transplantation (LT).
- “Despite metabolic comorbidities, posttransplant outcomes of NASH patients are generally good. In fact, 1-, 3-, and 5-year patient and graft survival rates are …similar to other liver diseases.”
- NASH/NAFLD can recur following LT…”NASH with significant fibrosis (stage ≥2) occurs in approximately 5% of recipients by 5 years after transplantation.”
- Additional issues to manage after LT, include weight management, and metabolic conditions including diabetes, hypertension, dyslipidemia, and hypertension. All of these conditions can be affected by specific immunosuppressants. For example, calcineurin inhibitors and corticosteroids can exacerbate type 2 diabetes mellitus.
My take: This article indicates better LT outcomes than I expected in patients with NASH/NAFLD.
Related blog posts: